The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
about
Prospects for dengue vaccines for travelersThe dengue vaccine pipeline: Implications for the future of dengue controlRapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell culturesRecent advances in understanding dengueA Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human PrimatesDengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesPrecisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody ResponsesVaccines and immunization strategies for dengue preventionCharacterization of cytopathic factors through genome-wide analysis of the Zika viral proteins in fission yeastCurrent progress in dengue vaccinesCharacterization of the ectodomain of the envelope protein of dengue virus type 4: expression, membrane association, secretion and particle formation in the absence of precursor membrane protein.In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.Dengue vaccines: recent developments, ongoing challenges and current candidates.Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders.Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.The burden of dengue and chikungunya worldwide: implications for the southern United States and CaliforniaThe contribution of non-human primate models to the development of human vaccinesIdentification of human neutralizing antibodies that bind to complex epitopes on dengue virionsSafety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine.Enhanced performance of an innovative dengue IgG/IgM rapid diagnostic test using an anti-dengue EDI monoclonal antibody and dengue virus antigen.Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding siteTargeting host factors to treat West Nile and dengue viral infections.DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice.Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice.Challenges for the formulation of a universal vaccine against dengue.Challenges in reducing dengue burden; diagnostics, control measures and vaccines.An update on Zika vaccine developments.Developing a dengue vaccine: progress and future challenges.Recent progress in dengue vaccine development.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.Generation and characterization of a monoclonal antibody against duck Tembusu virus envelope protein.A recombinant live attenuated tetravalent vaccine for the prevention of dengue.Dengue vaccines: what we know, what has been done, but what does the future hold?
P2860
Q26314423-3458FDE6-898B-4547-87D3-C31CE0C15002Q26314683-8BB3BD12-84D5-4029-9C59-C9EEEA1EA32EQ26700070-BB8C2308-E18D-44A8-ABEF-A433E1D0288DQ26766156-3C3776E4-74D3-4F48-98A4-8AF943CE5EABQ27116692-643C4A91-5BD3-47F1-90EC-638A357CE99EQ27304342-98C7C1E0-17FB-4F4F-9D6C-C11571FA69B4Q27493140-47FAE6B6-1E51-4DCC-8C5E-B04935FD6CE3Q28077521-7A95D73C-BB81-4A46-BB88-1596C7333135Q28114506-ECD25C72-7CB3-403C-A5A3-40E30198415BQ33408300-70604464-5811-4629-A885-ADD1A20E00A8Q33784307-294BFE21-F430-46F7-B4B0-CF9F5E01F209Q33867337-31B5B1FD-BC42-43FF-82FE-4A592ED51440Q34367194-225DB7C0-1007-4A67-970F-1A2C08590CAEQ34630584-DC3089FF-8135-402B-8BEC-94C92FB93BF8Q35548048-EF07CCE9-9DA4-4A6F-ACAC-DCBD2F9FFBECQ35594746-E0FC9D09-6764-4DC0-9C52-BD21474EBE51Q35737990-6704C683-358C-49AD-828C-8867E010BBF2Q35982791-EF35F33A-EB52-4A79-AF61-96677FB64CEAQ36026210-94451030-2329-4273-AD19-50F7E997D6BFQ36029040-78CA4738-C16A-4657-A250-BEFD0B06C535Q36363996-6CB6A88D-F21B-4D5D-8222-C32E4A1A9E19Q36616521-8E6BA0CA-60FE-4799-B2D6-2B2296CDAA08Q36667964-876F6A4C-429B-4483-9F01-BB0C368C9CC5Q36849774-479B060C-6434-40B1-9D62-441CE3426162Q37069430-38C835BA-406C-441E-8BAD-97BDE157089FQ37611829-F5C28EAD-AE81-4DAC-9230-A871C6FF3C12Q37694852-53F73B66-42BF-48F7-91DF-C0FCA72FCAFAQ37694855-B520839D-F728-4539-9429-7A83F20DE80DQ37721304-6AF05478-D548-431A-BD0A-09B456B0AE1EQ37736723-2581450E-49BE-4335-A8B8-33572039954BQ38121757-090A4934-CFDD-48C1-AD62-2AFDF95F75F5Q38140035-EF9D7A0F-2CBB-4E8A-8597-5BCCB8AE1B98Q38158670-AFF04917-9EC9-489F-9999-B7EA85E4F72DQ38201151-9E58AF7F-302D-4264-9021-2156191636F2Q38303232-58D42D13-7800-44E6-9B14-3BFCD42D3D6CQ38554795-EEE358E2-C5A9-4E09-9D71-C67D97414CECQ38658737-31550F34-9A7A-437A-A513-0F1987F51D33Q38721146-BD2B2F08-0849-4D55-8857-41B7BBBCB62BQ38738484-85F826AD-A39E-4760-BFB8-9AF48EFBF3FEQ38960985-1B007B4F-EA2E-4D76-A8B5-64C540684705
P2860
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The development of recombinant ...... dengue virus induced disease.
@en
The development of recombinant ...... dengue virus induced disease.
@nl
type
label
The development of recombinant ...... dengue virus induced disease.
@en
The development of recombinant ...... dengue virus induced disease.
@nl
prefLabel
The development of recombinant ...... dengue virus induced disease.
@en
The development of recombinant ...... dengue virus induced disease.
@nl
P2093
P2860
P1433
P1476
The development of recombinant ...... dengue virus induced disease.
@en
P2093
Andrew J Bett
Beth-Ann G Coller
David E Clements
Jan H Ter Meulen
Sangeetha L Sagar
P2860
P304
P356
10.1016/J.VACCINE.2011.07.021
P407
P577
2011-07-21T00:00:00Z